Frespaciguat
Phase 1Small molecule
Merck & Co.Frespaciguat is one of 65 small molecule programs targeting Hypoxemia. It is currently in Phase 1.
3
Indications
5
Total Trials
1
Active Trials
64
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
557 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Spiriva
Boehringer IngelheimPreclinical
Aclidinium Bromide
AstraZenecaPreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Proventil
Mylan Pharmaceuticals IncPreclinical
Insulin Therapy
SanofiPreclinical
Qvar
Chiesi Farmaceutici S.p.A.Preclinical
Curcumin
Merck & Co.Preclinical
Frespaciguat
Merck & Co.Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Single Dose1 trial
Hypoxemia1 trial
Chronic Obstructive Pulmonary Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Frespaciguat. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company